Key Points
- Boston Scientific CEO Michael Mahoney bought 186,240 shares at an average price of $48.33, investing approximately $9.0 million and increasing his stake by 13.27% to 1.59 million shares.
- The company recently beat quarterly expectations, reporting $0.86 in adjusted EPS and $5.44 billion in revenue, with revenue up 7.5% year over year. Management also authorized a $5 billion share-repurchase program.
- Analysts maintain a consensus “Moderate Buy” rating with an average price target of $71.62, although several firms recently lowered their targets; institutional investors own 89.07% of the stock.
Boston Scientific Corporation (NYSE:BSX - Get Free Report) Director David Habiger acquired 1,042 shares of the stock in a transaction on Monday, August 3rd. The stock was bought at an average cost of $48.07 per share, with a total value of $50,088.94. Following the completion of the transaction, the director owned 14,920 shares in the company, valued at $717,204.40. This trade represents a 7.51% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Boston Scientific Trading Down 2.8%
Shares of NYSE BSX opened at $47.73 on Thursday. Boston Scientific Corporation has a twelve month low of $42.20 and a twelve month high of $109.50. The company has a quick ratio of 1.22, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The business has a fifty day simple moving average of $45.72 and a two-hundred day simple moving average of $61.09. The firm has a market cap of $69.17 billion, a PE ratio of 19.32, a price-to-earnings-growth ratio of 1.07 and a beta of 0.56.
Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. During the same quarter in the previous year, the business posted $0.75 EPS. The company's quarterly revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.
Boston Scientific declared that its Board of Directors has initiated a share buyback plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's management believes its stock is undervalued.
Analyst Upgrades and Downgrades
Several research firms have issued reports on BSX. Oppenheimer cut their target price on Boston Scientific from $90.00 to $85.00 and set an "outperform" rating on the stock in a research note on Monday, July 27th. Citigroup cut their price target on shares of Boston Scientific from $70.00 to $61.00 and set a "buy" rating on the stock in a report on Thursday, July 30th. Daiwa Securities Group lowered Boston Scientific from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 29th. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and issued a $60.00 price objective on shares of Boston Scientific in a research report on Thursday, July 30th. Finally, Canaccord Genuity Group reduced their target price on Boston Scientific from $70.00 to $66.00 and set a "buy" rating on the stock in a research report on Thursday, July 30th. Twenty-four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $71.62.
Get Our Latest Research Report on BSX
Institutional Trading of Boston Scientific
Large investors have recently added to or reduced their stakes in the company. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific in the second quarter worth about $26,000. Swiss RE Ltd. purchased a new stake in Boston Scientific in the 4th quarter worth approximately $26,000. Garton & Associates Financial Advisors LLC purchased a new stake in Boston Scientific in the 4th quarter worth approximately $26,000. Clal Insurance Enterprises Holdings Ltd acquired a new stake in shares of Boston Scientific during the 1st quarter worth approximately $28,000. Finally, Sfam LLC purchased a new position in shares of Boston Scientific during the 4th quarter valued at approximately $29,000. Hedge funds and other institutional investors own 89.07% of the company's stock.
About Boston Scientific
(
Get Free Report)
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
